DK3125885T3 - Kombination af egfr-inhibitor og mek-inhibitor til anvendelse til behandling af nras-muteret cancer - Google Patents

Kombination af egfr-inhibitor og mek-inhibitor til anvendelse til behandling af nras-muteret cancer Download PDF

Info

Publication number
DK3125885T3
DK3125885T3 DK15715805.6T DK15715805T DK3125885T3 DK 3125885 T3 DK3125885 T3 DK 3125885T3 DK 15715805 T DK15715805 T DK 15715805T DK 3125885 T3 DK3125885 T3 DK 3125885T3
Authority
DK
Denmark
Prior art keywords
inhibitor
muterated
nras
cancer
treatment
Prior art date
Application number
DK15715805.6T
Other languages
English (en)
Inventor
Darren Anthony Edward Cross
Catherine Anne Eberlein
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3125885T3 publication Critical patent/DK3125885T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK15715805.6T 2014-04-04 2015-04-02 Kombination af egfr-inhibitor og mek-inhibitor til anvendelse til behandling af nras-muteret cancer DK3125885T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975088P 2014-04-04 2014-04-04
US201462013573P 2014-06-18 2014-06-18
PCT/GB2015/051042 WO2015150826A1 (en) 2014-04-04 2015-04-02 Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer

Publications (1)

Publication Number Publication Date
DK3125885T3 true DK3125885T3 (da) 2021-09-27

Family

ID=52824498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15715805.6T DK3125885T3 (da) 2014-04-04 2015-04-02 Kombination af egfr-inhibitor og mek-inhibitor til anvendelse til behandling af nras-muteret cancer

Country Status (15)

Country Link
US (2) US20200237758A1 (da)
EP (1) EP3125885B1 (da)
JP (1) JP6549147B2 (da)
KR (1) KR102406334B1 (da)
CN (1) CN106456774A (da)
AU (1) AU2015242407B2 (da)
CA (1) CA2943402C (da)
DK (1) DK3125885T3 (da)
ES (1) ES2890556T3 (da)
HU (1) HUE055747T2 (da)
MA (1) MA39841A (da)
MX (1) MX369111B (da)
PL (1) PL3125885T3 (da)
RU (1) RU2683276C2 (da)
WO (1) WO2015150826A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102444835B1 (ko) 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005534623A (ja) * 2002-04-08 2005-11-17 スミスクライン ビーチャム コーポレーション Erbファミリーの阻害剤並びにraf及び/又はras阻害剤を投与することを含む癌の治療法
JP2012508240A (ja) * 2008-11-11 2012-04-05 イーライ リリー アンド カンパニー P70s6キナーゼ阻害剤およびegfr阻害剤の併用療法
WO2013014448A1 (en) * 2011-07-27 2013-01-31 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
CN104093743B (zh) * 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
WO2014028909A1 (en) * 2012-08-16 2014-02-20 Ohio State Innovation Foundation Stat3 inhibitors and their anticancer use
US20140066465A1 (en) * 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
MA39841A (fr) 2017-02-08
MX369111B (es) 2019-10-29
CA2943402A1 (en) 2015-10-08
MX2016013048A (es) 2017-04-27
HUE055747T2 (hu) 2021-12-28
US20210177844A1 (en) 2021-06-17
JP2017511341A (ja) 2017-04-20
RU2016140626A3 (da) 2018-10-23
RU2683276C2 (ru) 2019-03-27
PL3125885T3 (pl) 2021-12-06
US20200237758A1 (en) 2020-07-30
JP6549147B2 (ja) 2019-07-24
ES2890556T3 (es) 2022-01-20
CN106456774A (zh) 2017-02-22
AU2015242407B2 (en) 2017-11-09
EP3125885A1 (en) 2017-02-08
CA2943402C (en) 2022-12-13
WO2015150826A1 (en) 2015-10-08
AU2015242407A1 (en) 2016-10-13
EP3125885B1 (en) 2021-06-30
KR20160135362A (ko) 2016-11-25
RU2016140626A (ru) 2018-05-07
KR102406334B1 (ko) 2022-06-07

Similar Documents

Publication Publication Date Title
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3227342T3 (da) Proteinøs heterodimer og anvendelse deraf
DK3325488T3 (da) Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3122358T3 (da) Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3253800T3 (da) Prostata antigen standarder og bruge deraf
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3174559T3 (da) Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
HK1259545A1 (zh) 用於治療癌症的bcl-2抑制劑和mek抑制劑組合產品
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse